Treatment with anti-PD1 or anti-PD-L1 was associated with a spectrum of complications and side effects, of which colitis, hepatitis, cardiovascular complications, and arthralgia were observed to be significantly different between nivolumab, pembrolizumab, atezolizumab, and durvalumab in the real-world experience. The gene discussed is CD274; the disease is hepatitis A virus infection.